A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy

Table 3 Patients and procedural characteristics

Source	Mean age, years	Cell type	Cell transplanted, n	Route of injection	Baseline LVEF, %
Bocchi EA et al. 2010 [11]	51 ± 15	BM-CD34+	0.96 × 10⁸	IC	21.8 ± 3.8
Vrtovec B et al. 2011 [6]	52 ± 8	BM-CD34+	1.23 ± 0.23 × 10⁸	IC	25.9 ± 4.6
Vrtovec B et al. 2013 [5]	53 ± 8	BM-CD34+	1.13 ± 0.26 × 10⁸	IC	24.0 ± 4.0
Martino H et al. 2015 [9]	51 ± 11	BM-MNCs	2.36 (1.76–2.95) × 10⁸	IC	24.0 ± 9.6
Henry TD et al. 2014 [10]	60 ± 16	BM-MNCs	1.65 (0.35–2.95) × 10⁸	IM	25.8 ± 7.0
Sant’Anna RT et al. 2014 [8]	48 ± 9	BM-MNCs	1.06 × 10⁸	IC	25.1 ± 4.0
Seth S et al. 2010 [7]	45 ± 15	BM-MNCs	1.68 ± 0.96 × 10⁸	IC	22.5 ± 8.3

BM bone marrow, IC intracoronary, IM intramyocardial, LVEF left ventricular ejection fraction, MNC mononuclear cell

ISSN: 1757-6512